Patent EP0225160A2 successfully refreshed from Google Patents.
EP0225160A2
Expired / Lapsed
EP
⏱️ 0.0 years remaining
Compositions and methods for the treatment of bleeding disorders
Assignee: Novo Nordisk Health Care AG
•
Filing: 1986-11-25
•
Granted: —
•
Expires: 2006-11-25
Abstract
Abstract A method for treating patients suffering from bleeding disorders not caused by clotting factor defects or clotting factor inhibitors, as well as a novel composition for use in treating bleeding disorders are disclosed.The method includes administering to a patient a composition comprising an effective haemostatic amount of factor VIIa, and is particularly effective in treating patients suffering from thromtocytopenia and von Willebrand's disease, as well as other platelet disorders. A composition suitable for use in treating such bleeding disorders comprises purified factor VIIa in a concentration of at least 25 µg/ml.
Inventors
- 👤 Ulla Karin Elisabeth Hedner
Bibliographic Details
Application Number
—
Jurisdiction
EP
Data Source
google_patents
Last Synchronized
2026-10-24 21:30
CPC Classifications
A; A61; A61L; A61L24/00; A61L24/04; A61L24/10; A61L24/108; A61K; A61K38/00; A61K38/16; A61K38/43; A61K38/46; A61K38/48; A61K38/482; A61K38/4846; A61K47/00; A61K47/02; A61K47/06; A61K47/08; A61K47/10; A61K47/16; A61K47/18; A61K47/183; A61K47/26; A61K47/30; A61K47/36; A61K47/42; A61K9/00; A61K9/0012; A61K9/0019; A61P; A61P7/00; A61P7/04; A61L2400/00; A61L2400/04
Claims Analysis
Total Claims: 18
Claim 1
Independent Claim
29 words
A composition for use in treating patients suffering from bleeding disorders not caused by clotting factor defects or clotting factor inhibitors comprising an effective haemostatic amount of factor VIIa.
Claim 2
Dependent Claim
29 words
A composition for use in treating patients suffering from bleeding disorders not caused by clotting factor defects or clotting factor inhibitors comprising an effective haemostatic amount of factor VIIa.
Claim 3
Dependent Claim
17 words
The composition according to claim l for use in treating patients suffering from thrombocytopenia or platelet disorders.
Claim 4
Dependent Claim
16 words
The composition according to claim l for use in treating patients suffering from von Willebrand's disease.
Claim 5
Dependent Claim
19 words
The composition according to claim l for use in treating patients suffering from bleeding in association with tissue damage.
Claim 6
Dependent Claim
18 words
The composition according to claim l comprising purified factor VIIa in a concentration of at least 25 µg/ml.
Claim 7
Dependent Claim
23 words
The composition of claim l wherein said haemostatic amount comprises from about l00 units to l000 units of factor VIIa/kg of body weight.
Claim 8
Dependent Claim
25 words
The composition of claim l wherein said haemostatic amount comprises from about l00 units to 500 units of factor VIIa per kg of body weight.
Claim 9
Dependent Claim
12 words
The composition of claim l wherein said composition further includes factor IX.
Claim 10
Dependent Claim
12 words
The composition of claim l including a physiologically acceptable carrier or diluent.
Claim 11
Dependent Claim
9 words
l0. The composition of claim l including an adjuvant.
Claim 12
Dependent Claim
10 words
The composition of claim l0 wherein said adjuvant is calcium.
Claim 13
Dependent Claim
24 words
The composition of claim l0 wherein said adjuvant is selected from the group consisting of albumin, non-reducing sugars, polyalcohols, amino acids, polysaccharides, and antioxidants.
Claim 14
Dependent Claim
30 words
The composition of claim l including a combination of calcium and one or more adjuvants selected from the group consisting of albumin, non-reducing sugars, polyalcohols, amino acids, polysaccharides and antioxidants.
Claim 15
Dependent Claim
38 words
The use of factor VIIa in the preparation of a composition for treating patients suffering from bleeding disorders not caused by clotting factor defects or clotting factor inhibitors which composition comprises factor VIIa in an effective haemostatic amount.
Claim 16
Dependent Claim
38 words
The use of factor VIIa in the preparation of a composition for treating patients suffering from bleeding disorders not caused by clotting factor defects or clotting factor inhibitors which composition comprises factor VIIa in an effective haemostatic amount.
Claim 17
Independent Claim
40 words
A method of preparing a composition for use in treating patients suffering from bleeding disorders not caused by clotting factor defects or clotting factor inhibitors, wherein purified factor VIIa is mixed with suitable adjuvant(s) and/or physiologically acceptable carrier or diluent.
Claim 18
Independent Claim
40 words
A method of preparing a composition for use in treating patients suffering from bleeding disorders not caused by clotting factor defects or clotting factor inhibitors, wherein purified factor VIIa is mixed with suitable adjuvant(s) and/or physiologically acceptable carrier or diluent.
References Cited (Backward Citations)
No citation records indexed.
USPTO Annuity & Maintenance Windows
Maintenance schedule is calculated for granted US utility patents.